SCHEMBL18172296

SCHEMBL18172296

CCN1CCOCC1c1cccnc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 5/20 0.49
CHRNB2 P17787 5/20 0.49
CHRNA4 P43681 5/20 0.49
ALDH1A1 P00352 3/20 0.47
CHRNB4 P30926 2/20 0.47
CHRNA3 P32297 2/20 0.47
CHRNA2 Q15822 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
LMNA P02545 1/20 0.47
HTR3E A5X5Y0 1/20 0.47
PSIP1 O75475 1/20 0.47
TRPA1 O75762 1/20 0.47
HTR3B O95264 1/20 0.47
CHRNA1 P02708 1/20 0.47
CHRNG P07510 1/20 0.47
MAPT P10636 1/20 0.47
CHRNB1 P11230 1/20 0.47
CYP2A6 P11509 1/20 0.47
PTGS1 P23219 1/20 0.47
CHRNA5 P30532 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13104784 0.82 P2RX7 (0.43) CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL15273881 0.82 P2RX7 (0.43) CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL4293001 0.81 CHRNB2 (0.61) CHRNA7CHRNB2CHRNA4ALDH1A1CHRNB4
SCHEMBL18862020 0.80 CHRNB2 (0.67) CHRNA7CHRNB2CHRNA4ALDH1A1CHRNB4
SCHEMBL18812558 0.79 CHRNA7 (0.43) CHRNA7CHRNB2CHRNA4ALDH1A1CHRNB4
SCHEMBL157171 0.78 ALDH1A1 (0.66) CHRNA7CHRNB2CHRNA4ALDH1A1CHRNB4
SCHEMBL29683697 0.78 ALDH1A1 (0.66) CHRNA7CHRNB2CHRNA4ALDH1A1CHRNB4
SCHEMBL28497766 0.78 ALDH1A1 (0.66) CHRNA7CHRNB2CHRNA4ALDH1A1CHRNB4
SCHEMBL29606745 0.78 ALDH1A1 (0.66) CHRNA7CHRNB2CHRNA4ALDH1A1CHRNB4
SCHEMBL4096638 0.78 CHRNA7 (0.47) CHRNA7CHRNB2CHRNA4ALDH1A1CHRNB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10011604-B2 Method of treatment using substituted imidazo[1,2b]pyridazine compounds ARRAY BIOPHARMA, INC. (US) 2018-07-03 US disclosed
EP-3286188-A1 ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES Cellcentric Ltd (GB) 2018-02-28 EP disclosed
WO-2016170323-A1 ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES CELLCENTRIC LTD (GB) 2016-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10011604-B2 Method of treatment using substituted imidazo[1,2b]pyridazine compounds COL2A1, COL1A1, IFNAR1 CHRNA7 205/4885CHRNB2 154/4885CHRNA4 358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.